ArticleBritish journal of clinical pharmacology2025
Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series.
Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
- Initial Dosage Optimization of Tacrolimus in Connective Tissue Disease-Associated Interstitial Lung Disease Patients: An Exploratory Study.Drug design, development and therapy · 2026Article
- Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs.Infection and drug resistance · 2026Review
- Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series.British journal of clinical pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tacrolimus is a cornerstone immunosuppressant in transplantation medicine with a narrow therapeutic window. Drug-drug interactions with strong CYP3A4 and P-glycoprotein modulators, such as rifampin and azole antifungals, significantly alter tacrolimus exposure and complicate therapy. Two transplant cases illustrates the impact of rifampin on tacrolimus pharmacokinetics. In one case, the tacrolimus dosage had to be increased to 120 mg/day during rifampin coadministration to maintain therapeutic concentrations, with a concentration-to-dose ratio (CDR) as low as 0.11 μg/L/mg. In both cases, cessation of rifampin led to a delayed but significant rise in tacrolimus levels, requiring substantial dose reductions within 7-15 days. These cases highlight the extreme variability in tacrolimus metabolism under the influence of rifampin and emphasize the need for daily therapeutic drug monitoring when starting, continuing and discontinuing rifampin. A multidisciplinary approach is essential and, when possible, the tacrolimus-rifampin combination should be avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.